Ready to answer the questions?
|
|
- Hope Howard
- 5 years ago
- Views:
Transcription
1 파워포인트문서의제목
2 Reference 1. IDSA GUIDELINES. Clinical Practice Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Disease Society of America. Clinical Infectious Diseases 2011;52(4):e56-e NCCN Guidelines. Version Prevention and Treatment of Cancer-Related Infections. 3. NCCN Guidelines. Version Myeloid Growth Factors 4. NCCN Guidelines. Version Myelodysplastic Syndromes 5. NCCN Guidelines. Version Acute Myeloid Leukemia Update of Recommendations for the Use of White Blood cell Growth Factors: An Evidence-Based Clinical Practice Guidelines. J Clin Oncol 2006;24(19): Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systemic Review. J Clin Oncol 2007;25: The role of granulocyte transfusions in neutropenic patients. British Journal of Haematology 2004;127:
3 Ready to answer the questions? Seven days after completing chemotherapy, B.C developed a fever of 102 F (orally). Vital signs are blood pressure, 109/70 mmhg; pulse, 102 beats/min; and respirations, 25 breaths/min. physical examination demonstrate a clear oropharynx without exudates or plaques. Chest and cardiac examination are normal. The exit site for the Hickman catheter is clean and nontender without signs of erythema or induration./ the perineum and rectum are nontender, and no masses are noted. Lab data; Hct 20%, Hbg 7g/dL, WBC 1,400 cells/mm3 with polymorphonuclear leukocytes, 1% band forms, 70% lymphocytes, 22% monocytes, PLT17,000 cells/l, blood glucose 160 mg/dl, serum creatinine 1.1 mg/dl, BUN 24 mg/dl What are the signs & symptoms of infection in B.C? What are the most common sites & sources of infection in patients such as B.C? Should B.C be started on antibiotic therapy immediately? What would be a reasonable initial empiric antibiotic regimen for B.C? Can any of the more potent, extended spectrum beta-lactams be used as monotherapy in febrile neutropenic patients? What is the rationale for adding vancomycin to the regimen? How should therapy be modified? For how long should antibiotics be continued? What is the significance of fungal infections in neutropenic cancer patients? Is there any way to facilitate marrow recovery and reduce the duration of neutropenia?
4 Overview Neutropenia : < 500 neutrophils/mcl or < 1,000 neutrophils/mcl and a predicted decline to 500/mcl over the next 48 h Fever : 38.3 C orally or 38.0 C over 1 h Major dose-limiting toxicity of chemotherapy Prolonged hospitalization Increase diagnostic and treatment costs Broad-spectrum antibiotic use Compromise clinical outcomes Prompt dose reduction or treatment delays in subsequent chemotherapy cycles
5 Management of neutropenic fever Principles for initial management of fever Antibiotic regimens for fever and infection Outpatient therapy Role of colony-stimulating factors Granulocyte transfusions Management of persistent fever Empiric fungal therapy Other causes of persistent fever and their management
6 Role of risk assessment Determine the type of empirical antibiotic therapy (oral vs intravenous) venue of treatment (inpatient vs outpatient) duration of antibiotic therapy Distinguish high-risk and low-risk patients with fever and neutropenia High risk patients Anticipated prolonged (> 7 days) & profound neutropenia (ANC < 100 cells/mm 3 ) Significant co-morbid conditions (hypotension, pneumonia, new-onset abdominal pain or neurologic changes) Inpatient status Hepatic insufficiency (> 5times ULN for aminotransferases) Renal insufficiency (CCR < 30 ml/min) Uncontrolled/progressive cancer Pneumonia or other complex infections at clinical presentation) Alemtuzumab Mucositis grade 3-4 Poor performancs status (ECOG 2)
7 Role of risk assessment The Multinational Association for Supportive Care in Cancer Risk-Index Score (MASCC) Burden of febrile neutropenia with no or mild symptoms No hypotension (systolic blood pressure >90 mmhg) No chronic obstructive pulmonary disease Solid tumor or hematologic malignancy with no previous fungal infection No dehydration requiring parenteral fluids Burden of febrile neutropenia with moderate symptoms Outpatient status Age <60 years High-risk patients ; MASCC score <21 Initially admitted to the hospital for empirical antibiotic therapy Low-risk patients ; MASCC score 21 Candidates for oral and/or outpatient empirical antibiotic therapy
8 Initial therapy for febrile neutropenia Infection risk assessment Potential infecting organisms Colonization Site of infection Local antibiotics susceptibility patterns Organ dysfunction/ drug allergy Broad spectrum of activity Previous antibiotic therapy Antipseudomonal coverage Bactericidal
9 Empiric antibiotic therapy what? Initial Monotherapy with an antipseudomonal β-lactam agent : Cefepime or ceftazidime, carbapenem, piperacillin-tazobactam Added to aminoglycosides, fluoroquinolones, and/or vancomycin Considered for suspected catheter-related infections, skin or softtissue infection, pneumonia, or hemodynamic instability MRSA : early addition of vancomycin, linezolid, or daptomycin VRE : early addition of linezolid, or daptomycin ESBLs : early use of a carbapenem KPCs : early use of polymymix-colstin or tigecycline Modification Others Penicillin-allergic patients : ciprofloxacin + clindamycin or aztreonam Oral empirical regimen : ciprofloxacin + amoxicillin-clavulanate Patients receiving fluoroquinolone prophylaxis should not receive oral empirical therapy with a fluoroquinolone.
10 Appropriate use of vancomycin Vancomycin should not be considered as a routine component of initial therapy for fever & neutropenia. Exception for serious infections Clinically apparent, serious, catheter-related infection Blood culture positive for G(+) bacteremia prior to final identification & susceptibility testing Known colonization with penicillin/cephalosporin-resistant pneumoccoci or MRSA Hypotension or septic shock without an identified pathogen Soft tissue infection Risk factors for viridans group streptococcal, bacteremia : severe mucositis & prophylaxis with quinolones or TMP-SMX Vancomycin should be discontinued in 2-3 days if a G(+) infection (eg, MRSA) is not identified. Linezolid, quinupristin/dalfopristin, and daptomycin may be used specifically for infections caused by documented VRE or in patients for whom vancomycin is not an option.
11 Empiric antibiotic therapy when, how? Guided by clinical & microbiologic data For the site & susceptibilities of any isolated organisms Unexplained persistent fever If hemodynamically unstable, coverage for resistant G(-), G(+), anaerobic fungi Vancomycin should be stopped after 2 days if no evidence for G(+) infection An IV-to-oral switch, if clinically stable & adequate gastrointestinal absorption If fever persists or recurs within 48 h in outpatients, hospital admission & with management as for high-risk patients Empirical antifungal coverage should be considered in high-risk patients who have persistent fever after 4-7 days of a broad-spectrum antibacterial regimen & no identified fever source.
12 Empiric antibiotic therapy how long? Time to defervescence ranges from 2 to 7 days (median, 5 days) for febrile cancer patients with neutropenia who receive appropriate initial antibiotic therapy. With clinically or microbiologically documented infections Continue for at least the duration of neutropenia (until ANC is 500 cells/mm 3 ) A defined course of therapy appropriate for the specific infection With unexplained fever The traditional endpoint is an increasing ANC > 500 cells/mm 3 With resolved signs & symptoms, remained neutropenia Oral fluoroquinolone prophylaxis until marrow recovery The patient is clinically well and afebrile for at least 24 hours before antibiotic discontinuation. With persistent fever (clinically stable patient) Modification of initial empiric antibiotic therapy based on specific new clinical findings and/or new microbiologic results
13 Antibiotic prophylaxis when, what? Fluoroquinolone prophylaxis (levofloxacin ciprofloxacin) for high-risk patients with expected durations of prolonged & profound neutropenia (ANC 100 cells/mm 3 for >7 days). Addition of a G(+) active agent to fluoroquinolone prophylaxis is generally not recommended. Not routinely recommended for low-risk patients who are anticipated to remain neutropenic for <7 days. Routine antibacterial prophylaxis was not recommended in patients undergoing high-dose therapy & autologous HSCT.
14 Antibacterial agents
15 Antibacterial agents
16 Antibacterial agents
17 Antifungal therapy ; empirical or prophylaxis With persistent or recurrent fever after 4-7 days of antibiotics & expected overall duration of neutropenia (>7 days) Data are insufficient to recommended a specific empirical antifungal agent for a patient already receiving antimold prophylaxis Prophylaxis against Candida infection such as allogenic hematopoietic stem cell transplant (HSCT) recipients or those undergoing intensive remission-induction or salvage-induction chemotherapy for acute leukemia. Fluconazole, itraconazole, voriconazole, posaconazole, micafungin, and caspofungin are all acceptable. In low-risk patients, routine use of empirical & prophylactic antifungal therapy is not recommended.
18 Antifungal agents
19 Antifungal agents
20 Antifungal agents
21 Antiviral therapy - prophylaxis Herpes simplex virus (HSV)-seropositive patients undergoing allogenic HSCT or leukemia induction therapy should receive acyclovir antiviral prophylaxis. Yearly influenza vaccination with inactivated vaccine is recommended for all patients being treated for cancer. Optimal timing of vaccination is not established, but serologic responses may be best between chemotherapy cycles (>7 days after the last treatment) or >2 weeks before chemotherapy starts.
22 Antiviral agents
23 Antiviral agents
24 Adjunctive therapies Adjunctive therapies Limited or anecdotal data are available to suggest that these interventions may be beneficial; GCSF or GMCSF should be considered in neutropenic patients with serious infectious complications, such as the following Pneumonia Invasive fungal infection Progressive infection (any type) Granulocyte transfusions Invasive fungal infection G(-) rod infection unresponsive to appropriate antimicrobial therapy Intravenous immunoglobulin Should be used in combination with ganciclovir for CMV pneumonia consider IV IgG for patients with profound hypogammaglobulinemia
25 Adjunctive therapies Prophylactic use of CSFs Risk assessment Evaluation of risk for chemotherapy-induced FN prior to the first cycle Disease type Chemotherapeutic regimen (high dose, dose dense or standard dose) Patients risk factors ; > 65 yrs, previous chemotherapy or radiotherapy, pre-existing neutropenia tumor involvement in the bone marrow, poor performance status comorbidities (renal or liver dysfunction) Treatment intent - curative/adjuvant - treatment directed toward prolongation of survival - symptom management therapy Based on the chemotherapy regimen & patient-related risk factors, the patient assigned to High risk group (< 20% ㅡ,risk of FN) Intermediate group (10-20% risk) Low risk group (< 10% risk)
26 Adjunctive therapies Efficacy of prophylactic CSFs
27 Adjunctive therapies Efficacy of prophylactic CSFs
28 Adjunctive therapies Efficacy of prophylactic CSFs
29 Adjunctive therapies Efficacy of prophylactic CSFs
30 Adjunctive therapies Apply prophylactic use of CSFs Risk of FN 20% (NCCN, ASCO, EORTC) Risk of < 20% + treatment intent chemotherapy or risky patient factors After the first cycle, patient evaluation should performed prior to each subsequent cycle to determine the risk categorization & treatment intent. If the patient experiences such as episode despite receiving CSF, recommends a chemotherapy dose reduction or change in treatment regimen unless there is an impact on patient survival. If the patient dose not develop FN or a dose-limiting neutropenic event and is thought to be benefiting from chemotherapy, the previous assessment should be repeated after each subsequent cycle.
31 Recommended for the prevention of FN in patients who have a high risk of FN based on age, medical history, disease characteristics, myelotoxicity of regimen Required and recommended for dose dense regimens Clinical trial data support the use of CSF when the risk of FN is in the range of 20% or higher Special circumstances often appropriate even with regimens with FN rates of < 20% Age > 65years / previous FN Poor performance status / poor nutritional status Open wounds or active infections More advanced cancer Cytopenias due to bone marrow involvement by tumor Extensive prior treatment Administration of combined chemoradiotherapy Other serious comorbidities
32 Examples of disease settings and chemotherapy regimens with a high risk febrile neutropenia (> 20%)
33 Examples of disease settings and chemotherapy regimens with a intermediate risk febrile neutropenia (10-20%)
34 Adjunctive therapies Therapeutic use of CSFs Compared to prophylactic use, there is less evidence supporting therapeutic use of CSFs for FN as an adjunctive to antibiotics. Patients with FN who are receiving prophylactic filgrastim or sargramostim should be continue with CSF therapy. Patients who have not received prophylactic CSFs, recommends an evaluation for risk factors for infection-related complications or poor clinical outcome. If risk factors are present, CSFs should be considered. Old age (> 65 years) Sepsis syndrome Severe (ANC < 100/mcl) or anticipated (> 10 days) neutropenia Pneumonia, invasive fungal infection, other clinically-documented infections Hospitalization Prior episode of FN
35 Should not be routinely used For patients with neutropenia who are afebrile As adjunctive treatment with antibiotic therapy for patients with fever and neutropenia Should be considered Patients with FN who are at high risk for infection-associated complications Patients who have prognostic factors that are predictive of poor clinical outcome High risk features Prolonged (> 10days) and profound neutropenia Age > 65 years Uncontrolled primary disease Pneumonia / Invasive fungal infection Sepsis syndrome (hypotension and multi-organ dysfunction) Being hospitalized at the time of fever development
36 Adjunctive therapies CSFs dosing & administration Severe chronic neutropenia : 6 mcg/kg bid non-myeloid malignancies At least 14 days between injection Insufficient evidence in use for primary prophylaxis
37 Adjunctive therapies Toxicity risks of CSFs
38 Adjunctive therapies Scheduled dose delivery of CSFs
39 CSF in older patients 65 years, diffuse aggressive lymphoma, curative chemotherapy Prophylactic CSF CSF in the pediatric population Primary prophylaxis with a likelihood of FN Secondary prophylaxis or therapeutic CSF should be limited to high-risk patients ALL children should be considered with caution CSF in patients with acute leukemia and myelodysplastic syndromes AML & ALL after the completion of the initial induction or first post-remission course MDS : in case of severe neutropenia & recurrent infection AML in relapse should be used judiciously, or not at all, in patients with refractory or relapsed myeloid leukemia since the expected benefit is only a few days of shortened neutropenia
40 CSF to increase chemotherapy dose-intensity and dose-density should only be used within an appropriately designed clinical trial CSF as adjuncts to progenitor-cell transplantation after autologous, but not allogenic, PBPC transplant is the current standard of care CSF in patients receiving radiotherapy with/without concurrent chemotherapy Chemoradiotherapy : should be avoided (particularly involving the mediastinum) Radiotherapy : in the absence of chemotherapy, therapeutic use of CSF may be considered Special comment (growth factors as treatment for radiation injury) patients exposed to lethal doses of total body radiotherapy, but not doses high enough to lead to certain death due to injury other organs, should receive prompt administration of CSF or pegylated GCSF Impact of CSF on quality of life and health care costs ; further research
41 Summary (ASCO 2006) Setting/indication Recommended Not recommended General FN risk in the range of 20% or higher circumstances Special circumstances Secondary prophylaxis Therapy of AFN Clinical factors dictate use Based on chemotherapy reaction among other factors Not to be used routinely Therapy of FN AML If high-risk for complications or poor clinical outcomes Following induction therapy, patients > 55years old most likely to benefit After the completion of consolidation chemotherapy Not to be used routinely as adjunctive treatment with antibiotic therapy Not to be used for priming effects ALL MDS Radiotherapy Older patients Pediatric population Radiation injury After the completion of initial chemotherapy or first post remission course Consider if receiving radiation therapy alone and prolonged delays are expected If 65 years old with diffuse aggressive lymphoma and treated with curative chemotherapy For the primary prophylaxis with a likelihood of FN & secondary prophylaxis or Tx for high-risk patients Prompt administration of CSF or pegylated G-CSF if exposed to lethal doses of total body radiotherapy Intermittent administration for a subset of patients with severe neutropenia & recurrent infection G-CSF use in children with ALL should be considered carefully
42 Adjunctive therapies Granulocyte transfusions One of the earliest approaches used to boost the patient s defense against infections was the transfusion of WBCs. In the 1970s, granulocyte transfusions were used adjunctively in patients with persistent neutropenia & documented infections who, despite appropriate antibiotics, failed to respond after 24 to 48 hours. This approach had limited value because of the difficulties in obtaining adequate cells for transfusion, as well as the problems with alloimmunization and risk of infection transmission. In addition, the questionable efficacy of WBC transfusions has decreased the use of this strategy. Therefore, granulocyte transfusions are not routinely indicated in this population. However, patients with progressive bacterial of fungal infections unresponsive to appropriate antimicrobial therapy may be considered as candidates.
43 Ready to answer the questions? Seven days after completing chemotherapy, B.C developed a fever of 102 F (orally). Vital signs are blood pressure, 109/70 mmhg; pulse, 102 beats/min; and respirations, 25 breaths/min. physical examination demonstrate a clear oropharynx without exudates or plaques. Chest and cardiac examination are normal. The exit site for the Hickman catheter is clean and nontender without signs of erythema or induration./ the perineum and rectum are nontender, and no masses are noted. Lab data; Hct 20%, Hbg 7g/dL, WBC 1,400 cells/mm3 with polymorphonuclear leukocytes, 1% band forms, 70% lymphocytes, 22% monocytes, PLT17,000 cells/l, blood glucose 160 mg/dl, serum creatinine 1.1 mg/dl, BUN 24 mg/dl What are the signs & symptoms of infection in B.C? What are the most common sites & sources of infection in patients such as B.C? Should B.C be started on antibiotic therapy immediately? What would be a reasonable initial empiric antibiotic regimen for B.C? Can any of the more potent, extended spectrum beta-lactams be used as monotherapy in febrile neutropenic patients? What is the rationale for adding vancomycin to the regimen? How should therapy be modified? For how long should antibiotics be continued? What is the significance of fungal infections in neutropenic cancer patients? Is there any way to facilitate marrow recovery and reduce the duration of neutropenia?
44
45
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationFebrile neutropenia. Febrile neutropenia. Febrile neutropenia. Febrile neutropenia 1/30/2019. Infection in patients with cancer
Manit Sae-teaw B.Pharm, BCP, BCOP Glad dip in pharmacotherapy Faculty of pharmaceutical sciences Ubon Ratchathani University Fever Oral temperature measurement of 38.3 C (101.0 F) single 38.0 C (100.4
More informationUPDATE ON FEBRILE NEUTROPENIA
UPDATE ON FEBRILE NEUTROPENIA Clinical approach and management Dr.Shafiq A. Alimad Head of medical department at university of science and technology hospital YICID 15-December-2014 INTRODUCTION Cancer
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationGuidelines in the Management of Febrile Neutropenia for Clinical Practice
REFERENCES 1. Tangka FK, Trogdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA. Cancer treatment cost in the United States: has the burden shifted over time? Cancer. 2010;116(14):3477-3484.
More informationShannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008
Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008 Study Title: Observational Study to Determine the Effect of an Emergency Department Adult Oncology Stat Antibiotic Protocol on Clinical Outcomes
More informationUICC EML Review 2014
UICC EML Review 2014 Granulocyte Stimulating Agents (G- CSF) Supplemental Document Many antineoplastic agents are cytotoxic to the bone marrow and prevent the development of granulocytes necessary to fight
More informationIDSA GUIDELINES EXECUTIVE SUMMARY
IDSA GUIDELINES Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America Alison G. Freifeld, 1 Eric
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationFEBRILE NEUTROPENIA CURRENT GUIDELINES FOR CHILDREN Alia Zaidi, MD. St. Jude International Outreach Program
SIOP PODC Supportive Care Education (ICON 2016) Presentation Date: 23 rd January 2016 Recording Link at www.cure4kids.org: https://www.cure4kids.org/ums/home/conference_rooms/enter.php?room=p25oti35nt7
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationGuideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation
Guideline for the Management of Fever Neutropenia in Children with Cancer /or Undergoing Hematopoietic Stem-Cell Transplantation COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive
More information2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More information8/11/2015. Febrile neutropenia Bone marrow transplant Immunosuppressant medications
Dean Van Loo Pharm.D. Febrile neutropenia Bone marrow transplant Immunosuppressant medications Steroids Biologics Antineoplastic Most data from cancer chemotherapy Bone marrow suppression Fever is the
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
More informationCANCER RELATED INFECTION AND USE OF COLONY STIMULATING FACTORS
CANCER RELATED INFECTION AND USE OF COLONY STIMULATING FACTORS Suphat Subongkot, Pharm.D, BCPS, BCOP Clinical Pharmacy, Khon Kaen University, Thailand Learning Objectives Summarize national guidelines
More informationCorporate Medical Policy
White Blood Cell Growth Factors Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: white_blood_cell_growth_factors 9/2016 4/2017 4/2018 6/2017 Description of
More informationDecember 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide
Severe Sepsis and Septic Shock Antibiotic Guide Surviving Sepsis: The choice of empirical antimicrobial therapy depends on complex issues related to the patient s history, including drug intolerances,
More informationChoc septique. Frédéric Pène
Choc septique Frédéric Pène Réanimation Médicale, Hôpital Cochin, AP-HP Université Paris Descartes Institut Cochin, Inserm U1016, CNRS UMR-8104, Département 3i No conflict of interest A 54 y.o. male patient
More informationNeupogen (Filgrastim)/Neulasta (Pegfilgrastim)
Policy Number Reimbursement Policy NEU12182013RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 12/18/2013 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine
More informationAntimicrobial Management of Febrile Neutropenic Sepsis
Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:
More informationReference No: SG 23/13
Title: Author(s) Ownership: Approval by: Guidelines for the use of granulocyte colony stimulating factor (GSCF) in adult oncology & malignant haematology patients Paula Scullin, Consultant Medical Oncologist,
More informationCircle Yes or No Y N. (Note: requests without this information will not be accepted.) [If no, then no further questions.]
04/25/2016 Prior Authorization AETA BETTER HEALTH OF LA MEDICAID Colony Stimulating Factors (LA88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationComparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia
Comparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia I. Malik ( National Cancer lnsititute, Karachi ) Shaharyar (, Department of Radiotherapy
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationCircle Yes or Y N. [Note: requests without this information will not be accepted.] [If no, then no further questions.
10/01/2016 Prior Authorization Aetna Better Health of West Virginia COLO STIMULATIG FACTORS (WV88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationNeutropenic Sepsis Acute General Management and Support. Ernie Marshall Macmillan Consultant in Medical Oncology Clatterbridge Centre for Oncology
Neutropenic Sepsis Acute General Management and Support Ernie Marshall Macmillan Consultant in Medical Oncology Clatterbridge Centre for Oncology Who Am I? I am A Medical Oncologist (MCCN) Site specialist
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 6 Last Review Date: September 15, 2017 Granix Description Granix (tbo-filgrastim)
More informationMANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSP There are no translations available. MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
More informationNeutropenic Fever 1 InpatientPediatric Treatment
Neutropenic Fever InpatientPediatric Treatment (Hematologic Cancers and Stem Cell Patients) te: This algorithm should not be used for patients receiving CAR cell therapy. Page of 8 Patient presents with
More informationNeutropenic Fever. CID 2011; 52 (4):e56-e93
Neutropenic Fever www.idsociety.org CID 2011; 52 (4):e56-e93 Definitions Fever: Single oral temperature of 101 F (38.3 C) Temperature 100.4 F (38.0 C) over 1 hour Neutropenia: ANC < 500 cells/mm 3 Expected
More informationFebrile Neutropenia. Laura J. Zitella, MS, RN, ACNP-BC, AOCN Nurse Practitioner Clinical Associate Professor University of California San Francisco
Febrile Neutropenia Laura J. Zitella, MS, RN, ACNP-BC, AOCN Nurse Practitioner Clinical Associate Professor University of California San Francisco What Are The Facts About Febrile Neutropenia (FN)? Fever
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationPerformance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients
DOI 10.1007/s00520-007-0347-3 ORIGINAL ARTICLE Performance of a modified MASCC index score for identifying low- febrile neutropenic cancer patients Luciano de Souza Viana & José Carlos Serufo & Manoel
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 7 Last Review Date: December 2, 2016 Granix Description Granix (tbo-filgrastim)
More informationFor peripheral blood stem cell (PBSC) mobilization prior to and during leukapheresis in cancer patients preparing to undergo bone marrow ablation
Last Review: 4/2010 NON-FORMULARY Clinical Guideline Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF), Neumega (oprelvekin; rh-il-11), Leukine (sargramostim; GM-CSF) Indications Neupogen
More informationRole of Pharmacist in Supportive care cancer
Role of Pharmacist in Supportive care cancer Manit Sae-teaw B.Pharm, BCOP, BCP Grad. Dip. In Pharmacotherapy Faculty of Pharmaceutical Science Ubon Ratchathani University 1 Outline Cancer facts Supportive
More informationNeutropenic Sepsis Guideline
Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline - definitions Suspected or proven infection in a neutropenic patient is a MEDICAL EMERGENCY and is an indication for immediate assessment and prompt
More informationMICHIGAN MEDICINE GUIDELINES FOR TREATMENT OF URINARY TRACT INFECTIONS IN ADULTS
When to Order a Urine Culture: Asymptomatic bacteriuria is often treated unnecessarily, and accounts for a substantial burden of unnecessary antimicrobial use. National guidelines recommend against testing
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Section: Prescription Drugs Effective Date: April 1, 2014 Subject: Granix 1 of 7 Last Review Date:
More informationSupplemental Online Case Discussion: Febrile Neutropenia
Supplemental Online Case Discussion: Febrile Neutropenia Alison C. Young, Fiona J. Collinson St James s Institute of Oncology, St James s University Hospital, Leeds, West Yorkshire, United Kingdom Case
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Subject: Granix 1 of 7 Last Review Date: September 18, 2015 Granix Description Granix (tbo-filgrastim)
More informationGuideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology
(G-CSF) for Adults in Oncology and Haematology For Use in: By: Oncology and Haematology Inpatients and Outpatients Oncologists and Haematologists For: Division responsible for document: Key words: Name
More informationSepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment
Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment What is sepsis? Life-threatening organ dysfunction caused by a dysregulated host response to infection A 1991 consensus
More informationLeukemias. Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College
Leukemias Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College Introduction Leukaemias are malignant disorders of the haematopoietic stem cell compartment,
More informationTop 5 papers in clinical mycology
Top 5 papers in clinical mycology Dirk Vogelaers Department of General Internal Medicine University Hospital Ghent Joint symposium BVIKM/BSIMC and SBMHA/BVMDM Influenza-associated aspergillosis in critically
More informationProphylaxis of febrile neutropenia :experiences with adjuvant TAC
Prophylaxis of febrile neutropenia :experiences with adjuvant TAC 30 th Apr, 2016 Jihyoun Lee Breast center, Department of Surgery Soonchunhyang University Hospital Chemotherapy and the risk of febrile
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationInfections in Oncology
Infections in Oncology Early Empiric Antibiotic Therapy for Febrile Neutropenia Patients at Low Risk Kenneth V. I. Rolston, MD, Edward B. Rubenstein, MD, of The University of Texas M.D. Anderson Cancer
More informationLCD for Sargramostim (GM-CSF, Leukine ) (L29275)
LCD for Sargramostim (GM-CSF, Leukine ) (L29275) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD ID Number L29275 LCD Information
More informationThe clinical implication and prognostic predictors of Tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii
Journal of Infection (2011) 63, 351e361 The clinical implication and prognostic predictors of Tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii R 陳南丞 VS 余文良醫師 本檔僅供內部教學使用檔案內所使用之照片之版權仍屬於原期刊公開使用時,
More informationESCMID Online Lecture Library. by author. CASE PRESENTATION ECCMID clinical grand round May Anat Stern, MD Rambam medical center Haifa, Israel
CASE PRESENTATION ECCMID clinical grand round May 2014 Anat Stern, MD Rambam medical center Haifa, Israel An 18 years old Female, from Ukraine, diagnosed with acute lymphoblastic leukemia (ALL) in 2003.
More informationBC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib
BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib Protocol Code Tumour Group Contact Physician ULKAMLAS Leukemia/BMT Dr. Donna Hogge ELIGIBILITY: Acute myeloid
More informationINTRODUCTION. O riginal A rticle. Singapore Med J 2012; 53(11) : 720
Singapore Med J 2012; 53(11) : 720 Risk factors for adverse outcomes and multidrugresistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital
More informationHow to prevent Infections in Patients undergoing allo-hsct?
How to prevent Infections in Patients undergoing allo-hsct? Olaf Penack EBMT Course, 29 Sept 1 Oct 2014, Naples, Italy #EBMT2014 www.ebmt.org Prevention of Infections Epidemiology and risk factors for
More informationAilyn T. Isais-Agdeppa, MD*, Lulu Bravo, MD*
A FIVE-YEAR RETROSPECTIVE STUDY ON THE COMMON MICROBIAL ISOLATES AND SENSITIVITY PATTERN ON BLOOD CULTURE OF PEDIATRIC CANCER PATIENTS ADMITTED AT THE PHILIPPINE GENERAL HOSPITAL FOR FEBRILE NEUTROPENIA
More informationLa neutropenia febbrile
XII Corso Avanzato di Terapia Antibiotica Pisa, 15-16 novembre 2017 La neutropenia febbrile Alessandra Micozzi Dipartimento di Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma Fever developing
More informationAdvanced Pediatric Emergency Medicine Assembly
(+)Joan Shook, MD, FACEP Professor of Pediatrics, Baylor College of Medicine; Chief Safety Officer and Chief Clinical Information Officer, Texas Children's Hospital Advanced Pediatric Emergency Medicine
More informationClinical characteristics and therapeutic outcome of patients with febrile neutropenia: Our clinical experience
International Journal of Clinical Medicine Research 2014; 1(1): 26-30 Published online April 30, 2014 (http://www.aascit.org/journal/ijcmr) Clinical characteristics and therapeutic outcome of patients
More informationSystematic Reviews in Hematological Malignancies
Systematic Reviews in Hematological Malignancies Pia Raanani, MD Davidoff Cancer Center Rabin Medical Center, Israel 1 2 Disorder CHMG Systematic review* Title Protocol Full Review Myelodysplastic syndrome
More informationClinical Policy: Pegfilgrastim (Neulasta) Reference Number: CP.CPA.127 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Neulasta) Reference Number: CP.CPA.127 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationPAEDIATRIC FEBRILE NEUTROPENIA CARE PATHWAY
PAEDIATRIC FEBRILE NEUTROPENIA CARE PATHWAY Purpose: This document is intended as a guide to the investigation and management of children presenting in Salisbury District Hospital with suspected neutropenic
More informationSUPPLEMENT ARTICLE DEFINITIONS
SUPPLEMENT ARTICLE The Infectious Diseases Society of America 2002 Guidelines for the Use of Antimicrobial Agents in Patients with Cancer and Neutropenia: Salient Features and Comments Kenneth V. I. Rolston
More informationCARE PATHWAY FOR CHILDREN AND YOUNG PERSONS WITH FEBRILE NEUTROPENIA, NEUTROPENIC SEPSIS OR SUSPECTED CENTRAL VENOUS LINE INFECTIONS
CARE PATHWAY FOR CHILDREN AND YOUNG PERSONS WITH FEBRILE NEUTROPENIA, NEUTROPENIC SEPSIS OR SUSPECTED CENTRAL VENOUS LINE INFECTIONS This Care Pathway has been developed by a multidisciplinary team. It
More informationTECHNICAL REPORT FOR THE DRUG SAFETY AND EFFECTIVENESS NETWORK:
TECHNICAL REPORT FOR THE DRUG SAFETY AND EFFECTIVENESS NETWORK: INTERVENTIONS FOR THE PROPHYLAXIS AND TREATMENT OF VIRAL, FUNGAL, AND BACTERIAL INFECTIONS IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC
More informationAcute Cholangitis. Kelsey Knotts PharmD Candidate Class of 2016
Acute Cholangitis Kelsey Knotts PharmD Candidate Class of 2016 Learning Objectives 1. Describe the mechanism of the development of acute cholangitis 2. Identify common causative organisms in acute cholangitis
More informationPekka Riikonen. Introduction
Recombinant Human Granulocyte-Macrophage Colony-S timulating Factor in Combination with Antibiotics in the Treatment of Febrile Neutropenia in Children Pekka Riikonen Kuopio University Hospital, Division
More informationSepsi: nuove definizioni, approccio diagnostico e terapia
GIORNATA MONDIALE DELLA SEPSI DIAGNOSI E GESTIONE CLINICA DELLA SEPSI Giovedì, 13 settembre 2018 Sepsi: nuove definizioni, approccio diagnostico e terapia Nicola Petrosillo Società Italiana Terapia Antiinfettiva
More informationFebrile Neutropenia in Intensive Care Unit
ICU Rounds Febrile Neutropenia in Intensive Care Unit Nattamol Hosiriluck MD, Saba Radhi MD Abstract Febrile neutropenia is a serious complication of cancer treatment and causes significant morbidity and
More informationamphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET
4 17 9 27 17 1 7 amphotericin B 34 empiric therapy; ET preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET Key words: antifungal therapyempiric therapypreemptive
More informationNeutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt
Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte
More informationThis is a controlled document and therefore must not be changed
AZACITIDINE NICE TA218 Treatment of adults not eligible for haematopoietic stem cell transplantation who have: Intermediate-2 and high-risk MDS according to the International Prognostic Scoring System
More informationPREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS
PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.08 Subject: Leukine Page: 1 of 6 Last Review Date: March 13, 2014 Leukine Description Leukine (sargramostim)
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationPublished Ahead of Print on January 14, 2013 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on January 14, 2013 as 10.1200/JCO.2012.45.8661 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2012.45.8661 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I
More informationMortality Rate was unsightly!!! 4/24/2013. Sepsis Quality Improvement Project
Libby, MT Sepsis Quality Improvement Project Barb Dumont RN, Director of Quality and Risk Management Mike Julius RN, ED Manager Cathy Wolfe RN, Chief Nursing Officer. Mortality Rate was unsightly!!! percent
More informationTitle: Author: Speciality / Division: Directorate:
Antifungal guidelines for CANDIDIASIS INFECTIONS (Adults) Proven infection: Targeted antifungal therapy should be prescribed for: o Positive cultures from a sterile site with clinical or radiological abnormality
More informationInitial Resuscitation of Sepsis & Septic Shock
Initial Resuscitation of Sepsis & Septic Shock Dr. Fatema Ahmed MD (Critical Care Medicine) FCPS (Medicine) Associate professor Dept. of Critical Care Medicine BIRDEM General Hospital Is Sepsis a known
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs.
More informationEvaluation of Febrile Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation
ORIGINAL REPORT Evaluation of Febrile Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation Shahideh Amini 1, Molouk Hadjibabaie 2, Zahra Jahangard-Rafsanjani 1, Asieh Ashuri 3, Hassan
More informationInfection and Immune Reconstitution: The NEW Forms
Infection and Immune Reconstitution: The NEW Forms Marcie Tomblyn, MD, MS Assistant Professor, UMN Assistant Scientific Director, CIBMTR Minneapolis February 16, 2006 Why the changes? Infection data not
More informationPhysician's Core Measure Pocket Guide AMI
Physician's Core Measure Pocket Guide Core Measure Hotline: Ext. 4448 http://centegramedsource.com Indicator: AMI AMI VER. 9/2018 MUST document WHY no ASA unless there is documentation of contraindication
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Febrile Neutropenia. These podcasts are designed to give medical students an overview of key topics in pediatrics. The
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationProphylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?
TIMM-4 18-21 October 2009 Athens, Greece Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Azacitidine i INDICATION ICD10 Regimen Code *Reimbursement Status Intermediate-1 and low risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System
More informationCare Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT
Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: All MHS employed providers within Primary Care, Urgent Care, and In-Hospital Care. The secondary audience
More informationMONTEFIORE MEDICAL CENTER
DEPARTMENT OF PHARMACY MONTEFIORE MEDICAL CENTER SUBJECT: MANUAL CODE: Restricted Drugs Policy, Antibiotic Restriction PH-R-5 DATE ISSUED: August, 1976 DATE REVISED: September 2000, October 2003, September
More informationDrug Typical Dose CrCl (ml/min) Dose adjustment for renal insufficiency Acyclovir PO (HSV) 400 mg TID >10 <10 or HD PD
Antimicrobial Dosing in Renal Insufficiency (Adults) ASP Handbook * In patients on hemodialysis (), give antimicrobial immediately after dialysis on dialysis days. = Intermittent hemodialysis = Peritoneal
More informationHematologic Safety Profile of Linezolid in the Early Periengraftment Period after Allogeneic Stem Cell Transplantation
Hematologic Safety Profile of in the Early Periengraftment Period after Allogeneic Stem Cell Transplantation Nina Cohen, 1 Coralia N. Mihu, 3 Susan K. Seo, 1 Dick Chung, 1 Joanne Chou, 2 Glenn Heller,
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationReference: NHS England 1602
Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC
More information